Abstract
Methotrexate (MTX) is an antimetabolite with a major role in the treatment of acute lymphoblastic leukaemia (ALL). The authors report the management of a 9-year-old boy who developed an anaphylactoid reaction to high-dose MTX infusion, after a first challenge with intrathecal administration, during induction therapy for ALL. A desensitization protocol was followed and MTX tolerance has been successfully achieved, allowing this patient to complete the needed chemotherapy.
MeSH terms
-
Anaphylaxis / chemically induced*
-
Anaphylaxis / therapy*
-
Antimetabolites, Antineoplastic / administration & dosage*
-
Antimetabolites, Antineoplastic / adverse effects*
-
Child
-
Desensitization, Immunologic*
-
Drug Hypersensitivity / therapy*
-
Humans
-
Injections, Spinal
-
Leukemia-Lymphoma, Adult T-Cell / complications
-
Leukemia-Lymphoma, Adult T-Cell / drug therapy*
-
Male
-
Methotrexate / administration & dosage*
-
Methotrexate / adverse effects*
Substances
-
Antimetabolites, Antineoplastic
-
Methotrexate